This manuscript is a secondary analysis of a large multicenter randomized controlled trial. The primary study is Cross RK et al., A Randomized Controlled Trial of TEL-Emedicine for patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol, 2019 Mar. https ://doi. org/10.1038/s4139 5-018-0272-8. Fig. 1 is adapted from a similar figure in the primary study referenced above.
In Table 1 , the participant sample sizes are entered incorrectly. They should be n = 187 total participants, n = 65 in the standard care arm, n = 65 in the TELE-IBD EoW arm, and n = 57 in the TELE-IBD weekly arm.
Exclusion criteria can be found in the Study Participants section of the Methods.
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